February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Recent evidence suggests a potential link between semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight loss, and alopecia. Studies, including a retrospective cohort study by Burke et al. and a scoping review by Tran et al., indicate an increased incidence of hair loss associated with semaglutide. A disproportionality analysis by Godfrey et al. supports these findings, though causality is not confirmed. The rapid weight loss from semaglutide may lead to nutritional deficiencies and endocrine disruptions, contributing to hair loss. The psychosocial impact of alopecia is significant, affecting patient well-being and treatment adherence. There is a critical need for comprehensive clinical trials to confirm these associations and guide safer clinical practices.